The FDA is reviewing durvalumab with enfortumab vedotin for patients with muscle-invasive bladder cancer who cannot receive ...

PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Radical cystectomy involves bladder removal and urinary diversion, often using a laparoscopic robot-assisted approach for precision and access. The surgery lasts four to six hours, with a recovery ...

Removal of the bladder, called radical cystectomy, is the preferred treatment for patients with muscle-invasive bladder cancer (MIBC) as well as for some with non-muscle-invasive bladder cancer (NMIBC ...

American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...

RARC with intracorporeal urinary diversion offers survival outcomes similar to those of open radical cystectomy, but is associated with better perioperative outcomes. Real-world data support the ...

AstraZeneca (NYSE: AZN) said the U.S. Food and Drug Administration has accepted and granted Priority Review to a supplemental Biologics License Application for Imfinzi (durvalumab) in combination ...

Partial cystectomy for muscle-invasive bladder cancer offers metastasis- and cancer-free survival comparable to that of radical cystectomy, but with less perioperative morbidity. Partial and radical ...